Month: August 2021

Kering Société anonyme with a capital of € 500,071,664 Head office : 40, rue de Sèvres – 75007 PARIS 552 075 020 RCS PARIS   August 24, 2021   Statement in compliance with article 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers)      Date     Total Number of shares   Total number of voting rights  theoretical 1 Exercisable 2  August 15, 2021   125,017,916   177,812,812   177,513,101    1 Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations).   2 Excluding treasury shares stripped of voting rights.  AttachmentKering – Statement Number of Shares and voting rights – 08.15.2021

ATLANTA , Aug. 24, 2021 (GLOBE NEWSWIRE) —WHO: First Advantage (NASDAQ: FA), a leading global provider of technology solutions for screening, verifications, safety and compliance related to human capital   WHAT: Will host a webinar series exploring the state of drug screening.   WHEN: “In the Weeds on Today’s Drug Testing Landscape” will take place on Tuesday, August 31, 2021, at 1:00 p.m. ET.     “The New Future of Drug Screening” will be held on Thursday, September 23, 2021, at 1:00 p.m. ET   WHERE:   To sign up for the August 31 event, click here. To register for the September 23 webinar, click here.DETAILS: According to a June 2021 report from the American Medical Association, COVID-19 has increased drug abuse. Information from health agencies, law enforcement, emergency medical services,...

Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML Patients HOUSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug (IND) application for BP1002 (liposomal Bcl-2), the Company’s second drug candidate, for an initial Phase 1/ 1b clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia (AML) patients. “AML patients that fail frontline venetoclax-based therapy have very poor prognosis with a median overall survival...

Verkkokauppa.com Oyj                STOCK EXCHANGE RELEASE         24 August, 2021 at 2:00pm EEST Verkkokauppa.com strengthens its management team to support strategy implementation and business development Verkkokauppa.com Oyj focuses on putting its new strategy into action, refreshes the composition of its management team and appoints a new Chief Strategy and Development Officer. Jyrki Tulokas (KTM) has been appointed Chief Technology Officer of Verkkokauppa.com. Prior to his new position, Jyrki worked at F-Secure in several management positions and has been a member of the management team since 2016, serving as Executive Vice President of Strategy and Business Development, Cyber Security Products and Services, and, most recently, as CTO. In his new role at Verkkokauppa.com, Jyrki will become a member of the management team, reporting...

Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ), a global leader in cloud communications for mobile customer engagement, today announced that Christina Raaschou joins the Sinch management team as Chief Human Resources Officer. She will assume her role on January 10, 2022. Christina Raaschou has a broad experience of Human Resources and change management with particular focus on international technology organizations. She joins Sinch from a current role at H&M Group, where she is responsible for Human Resources within the global technology organization H&M Group Business Tech. Prior to this, Christina has had leading roles in Human Resources at Unilever and Ericsson and assignments within international recruitment and Executive Search. Sinch’s strategic focus is to drive profitable growth through organic expansion...

PRESS RELEASE Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma FDA grants Priority Review to tebentafusp for the treatment of HLA-A*02:01-positive patients with metastatic uveal melanoma; with an expected Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2022 EMA Committee for Medicinal Products for Human Use accepted tebentafusp Marketing Authorization Application and will review under Accelerated Assessment Procedure (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, August 24, 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR)...

Figure #1 – North Limb Project Drill Grids Plan MapFigure #1 – North Limb Project Drill Grids Plan MapFigure #2 – Armand Lake Volcanic Complex Drillhole Plan MapFigure #2 – Armand Lake Volcanic Complex Drillhole Plan MapFigure #3: Section A-150 (NL21-06)Figure #3: Section A-150 (NL21-06)Figure #4: Section A+725 (NL21-07, NL21-08)Figure #4: Section A+725 (NL21-07, NL21-08)Figure #5: Section A+475 (NL21-09)Figure #5: Section A+475 (NL21-09)TORONTO, Aug. 24, 2021 (GLOBE NEWSWIRE) — Hemlo Explorers Inc. (the “Company”) (TSXV: HMLO) is pleased to provide an update on its drill program at the North Limb project, located 15 km north of the Hemlo Mine near Manitouwadge, Ontario.   Highlights:Two drill grids have been instituted to cover the entire North...

In vitro and in vivo data demonstrate favorable safety and potency against multiple dengue virus serotypes supporting ongoing clinical development of AT-752Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 400 million infections each year globallyBOSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of data demonstrating the in vitro and in vivo activity of AT-752 against dengue virus infection, in the journal, Antimicrobial Agents and Chemotherapy. The article titled, “Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses,” can be accessed here. The published data demonstrate that AT-752 has...

Company Plans to Submit an IND to Support a Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Brain Fog Overlap with Symptoms of Fibromyalgia, for which TNX-102 SL is in Mid-Phase 3 Development Long COVID Afflicts More Than 30% of Patients Following Infection with SARS-CoV-2, the Virus that Causes COVID-19, and is Expected to be a Global Health Burden CHATHAM, N.J., Aug. 24, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it received the official minutes from a Type B pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) to develop TNX-102 SL1 (cyclobenzaprine HCl sublingual tablets) as...